XML 41 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Revenues
 3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenues
Product Revenue
Revenue by product is summarized as follows:
 For the Three Months Ended March 31,
20212020
(In millions)United
States		Rest of
World		TotalUnited
States		Rest of
World		Total
Multiple Sclerosis (MS):
Fumarate*$236.0 $316.9 $552.9 $777.5 $323.3 $1,100.8 
Interferon**241.8 158.7 400.5 292.6 173.4 466.0 
TYSABRI273.3 230.0 503.3 277.7 244.7 522.4 
FAMPYRA— 26.6 26.6 — 28.3 28.3 
Subtotal: MS product revenue751.1 732.2 1,483.3 1,347.8 769.7 2,117.5 
Spinal Muscular Atrophy:
SPINRAZA148.7 371.8 520.5 235.4 329.6 565.0 
Biosimilars:
BENEPALI— 121.7 121.7 — 133.5 133.5 
IMRALDI— 57.9 57.9 — 61.6 61.6 
FLIXABI— 25.5 25.5 — 23.7 23.7 
Subtotal: Biosimilar product revenue— 205.1 205.1 — 218.8 218.8 
Other:
FUMADERM— 2.8 2.8 — 3.3 3.3 
Total product revenue$899.8 $1,311.9 $2,211.7 $1,583.2 $1,321.4 $2,904.6 
*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.
**Interferon includes AVONEX and PLEGRIDY.
We recognized revenue from two wholesalers accounting for 30.0% and 9.3% of gross product revenue for the three months ended March 31, 2021, and 30.0% and 14.6% for the three months ended March 31, 2020.
An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions)DiscountsContractual
Adjustments		ReturnsTotal
Balance, December 31, 2020$141.4 $1,093.0 $41.6 $1,276.0 
Current provisions relating to sales in current year185.1 775.7 3.8 964.6 
Adjustments relating to prior years0.9 (32.1)1.0 (30.2)
Payments/credits relating to sales in current year(111.8)(284.8)— (396.6)
Payments/credits relating to sales in prior years(82.8)(562.9)(1.7)(647.4)
Balance, March 31, 2021$132.8 $988.9 $44.7 $1,166.4 
The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions)As of March 31, 2021As of December 31, 2020
Reduction of accounts receivable$173.4 $195.4 
Component of accrued expense and other993.0 1,080.6 
Total revenue-related reserves$1,166.4 $1,276.0 
Revenue from Anti-CD20 Therapeutic Programs
Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
 For the Three Months Ended March 31,
(In millions)20212020
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA$174.1 $341.3 
Other revenue from anti-CD20 therapeutic programs214.9 179.1 
Total revenue from anti-CD20 therapeutic programs$389.0 $520.4 
For additional information on our collaboration arrangements with Genentech, please read Note 18, Collaborative and Other Relationships, to our consolidated financial statements included in our 2020 Form 10-K.
Other Revenue
Other revenue is summarized as follows:
 For the Three Months Ended March 31,
(In millions)20212020
Revenue from collaborative and other relationships:
Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis$3.9 $3.7 
Other revenue from collaborative and other relationships— 0.2 
Other royalty and corporate revenue:
Royalty6.2 11.4 
Other corporate83.2 94.0 
Total other revenue$93.3 $109.3